# Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF

> **NCT05577819** · NA · RECRUITING · sponsor: **Massachusetts General Hospital** · enrollment: 515 (estimated)

## Conditions studied

- Transthyretin Amyloidosis
- Heart Failure
- Heart Failure, Diastolic
- Amyloidosis

## Interventions

- **DIAGNOSTIC_TEST:** 99mTc-pyrophosphate Scintigraphy

## Key facts

- **NCT ID:** NCT05577819
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-10-02
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-12-31
- **Target enrollment:** 515 (ESTIMATED)
- **Last updated:** 2024-12-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05577819

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05577819, "Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05577819. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*